Equitec Proprietary Markets, LLC Revance Therapeutics, Inc. Transaction History
Equitec Proprietary Markets, LLC
- $137 Million
- Q1 2025
A detailed history of Equitec Proprietary Markets, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Equitec Proprietary Markets, LLC holds 300 shares of RVNC stock, worth $771. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300Holding current value
$771% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RVNC
# of Institutions
33Shares Held
10.6MCall Options Held
370KPut Options Held
0-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL423KShares$1.09 Million0.0% of portfolio
-
Rothschild & CO Asset Management Us Inc. New York, NY370KShares$949,9950.1% of portfolio
-
International Biotechnology Trust PLC London, X0289KShares$742,0251.12% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL237KShares$610,1410.0% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...